Regeneration of bifurcation in beagle dogs: histologic evaluation of two regeneration materials

The aim of this study was to compare Emdogain and Guidor resorbable materials in the regeneration and/or healing of experimental Class II furcation lesions. Class II premolar furcation defects 3-5 mm high and 2.5-5 mm deep were experimentally induced in four beagle dogs. Dogs 1 and 2were assigned to one-stage surgery where the defect created was immediately followed by the placement of either Guidor or Emdogain or nothing (control). Dogs 2 and 4 were assigned to a two-stage approach where the creation of the defect was followed one month later with the membrane placement or nothing (control). After six months of healing animals were sacrificed. Subsequently, decalcified sections were prepared from all animals and used for histological evaluation. Accelular cementum was not a constant finding with the use of Emdogain. It was concluded that the two-stage surgery approach is a more predictable experimental model for the healing of Class II furcation.King Saud Universit

Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation Program

Establishing a hematopoietic cell transplantation (HCT) program is complex. Planning is essential while establishing such a program to overcome the expected challenges. Authorities involved in HCT program establishment will need to coordinate the efforts between the different departments required to start up the program. One essential department is pharmacy and the medications required. To help facilitate this, the Worldwide Network for Blood and Marrow Transplantation organized a structured survey to address the essential medications required to start up an HCT program. A group of senior physicians and pharmacists prepared a list of the medications used at the different phases of transplantation. These drugs were then rated by a questionnaire using a scale of necessity based on the stage of development of the transplant program. The questionnaire was sent to 30 physicians, in different parts of the world, who have between 5 and 40 years of experience in autologous and/or allogeneic transplantation. This group of experts scored each medication on a 7-point scale, ranging from an absolute requirement (score of 1) to not required (score of 7). The results are presented here to help guide the prioritization of required medications